Your browser doesn't support javascript.
loading
Ibrutinib dose intensity in high-risk chronic lymphocytic leukemia.
Forestieri, Gabriela; Terzi di Bergamo, Lodovico; Deodato, Marina; Frustaci, Anna Maria; Moia, Riccardo; Deambrogi, Clara; Rasi, Silvia; Autore, Francesco; Merli, Michele; Mattarucchi, Roberta; Fahrni, Gaby; Scarfo', Lydia; Gussetti, Daniela; Bulian, Pietro; Zanatta, Annagiulia; Spina, Valeria; Bruscaggin, Alessio; Pini, Katia; Piffaretti, Deborah; Pirosa, Maria Cristina; Salehi, Matin; Marques de Almeida, Joyce; Passweg, Jakob; Cavalli, Franco; Zucca, Emanuele; Gerber, Bernhard; Stussi, Georg; Gattei, Valter; Ghia, Paolo; Gregor, Michael; Passamonti, Francesco; Laurenti, Luca; Gaidano, Gianluca; Tedeschi, Alessandra; Rossi, Davide; Condoluci, Adalgisa.
Afiliación
  • Forestieri G; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Terzi di Bergamo L; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Deodato M; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Frustaci AM; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
  • Moia R; Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
  • Deambrogi C; Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
  • Rasi S; Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
  • Autore F; Hematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
  • Merli M; Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
  • Mattarucchi R; Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
  • Fahrni G; Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
  • Scarfo' L; Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
  • Gussetti D; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Bulian P; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Zanatta A; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Spina V; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Bruscaggin A; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Pini K; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Piffaretti D; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Pirosa MC; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Salehi M; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Marques de Almeida J; Laboratory of Experimental Hematology, Institute of Oncology Research, Bellinzona, Switzerland.
  • Passweg J; Clinic of Haematology, University Hospital Basel, Basel, Switzerland.
  • Cavalli F; Institute of Oncology Research, Bellinzona, Switzerland.
  • Zucca E; Clinic of Oncology, Oncology Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Gerber B; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
  • Stussi G; Clinic of Hematology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Gattei V; Faculty of Biomedical Sciences, Università della Svizzera Italiana, Lugano, Switzerland.
  • Ghia P; Clinic of Hematology, Institute of Southern Switzerland, Ente Ospedaliero Cantonale, Bellinzona, Switzerland.
  • Gregor M; Clinical and Experimental Onco-Hematology Unit, Centro di Riferimento Oncologico di Aviano (CRO), IRCCS, Aviano, Italy.
  • Passamonti F; Strategic Research Program on CLL, Division of Experimental Oncology, IRCCS San Raffaele Scientific Institute and Vita-Salute San Raffaele University, Milan, Italy.
  • Laurenti L; Division of Hematology, Cantonal Hospital of Lucerne, Lucerne, Switzerland.
  • Gaidano G; Ospedale di Circolo of Varese & Department of Medicine and Surgery, Hematology, ASST Sette Laghi, University of Insubria, Varese, Italy.
  • Tedeschi A; Hematology Institute, Catholic University of the Sacred Hearth, Fondazione Policlinico Universitario A. Gemelli, Rome, Italy.
  • Rossi D; Department of Translational Medicine, Division of Hematology, University of Eastern Piedmont, Novara, Italy.
  • Condoluci A; Department of Hematology, ASST Grande Ospedale Metropolitano Niguarda, Milan, Italy.
Hematol Oncol ; 40(5): 1100-1104, 2022 12.
Article en En | MEDLINE | ID: mdl-35613703
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Suiza
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Colección: 01-internacional Banco de datos: MEDLINE Asunto principal: Leucemia Linfocítica Crónica de Células B Tipo de estudio: Etiology_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: Hematol Oncol Año: 2022 Tipo del documento: Article País de afiliación: Suiza